Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Gilead Sciences Stories

2014-01-08 08:28:31

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 8, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Express Scripts Holding Company (NASDAQ: ESRX), Sanofi SA (ADR) (NYSE: SNY), Agilent Technologies Inc. (NYSE: A) and Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH). Today's readers may access these reports free of charge - including full price targets,...

2014-01-06 08:26:28

NEW YORK, Jan. 6, 2014 /PRNewswire/ -- Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510 million in cash. (Logo: http://photos.prnewswire.com/prnh/20130812/NY62264LOGO) The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec's TECFIDERA® (dimethyl fumarate), an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis. The...

2013-12-19 10:38:09

Biological markers confirm behavioral data; underscore drug's effectiveness In 2012 the HIV antiretroviral drug Truvada became the first and only medication approved by the FDA for HIV prevention. Led by Gladstone Institutes' Investigator Robert Grant, MD, MPH, this research was hailed as an important step towards reducing the worldwide HIV/AIDS epidemic. Now, a new study provides further proof that regular Truvada use can reduce one's risk for contracting HIV—without increasing sexual...

2013-12-17 08:26:07

NEW YORK, December 17, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), St. Jude Medical Inc. (NYSE: STJ), Cigna Corp. (NYSE: CI), Pharmacyclics Inc. (NASDAQ: PCYC), and LifePoint Hospitals Inc. (NASDAQ: LPNT). Today's readers may access these reports free of charge - including full price targets, industry analysis...

2013-12-11 08:35:41

HONG KONG, Dec. 11, 2013 /PRNewswire/ -- Insiderslab.com reveals the performance of company insiders from the insider trading reports. Today's reports will cover the following stocks: Gilead Sciences (NASDAQ:GILD), Microsoft (NASDAQ:MSFT), Halliburton (NYSE:HAL), Twitter (NYSE:TWTR), Micron (NASDAQ:MU), and Tesla Motors (NASDAQ:TSLA). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...

FDA Approves Sovaldi For Treatment Of Chronic Hepatitis C
2013-12-08 07:27:34

redOrbit Staff & Wire Reports – Your Universe Online Sovaldi (sofosbuvir), a new drug that can treat hepatitis C infections, has been approved for sale by the US Food and Drug Administration (FDA), agency officials confirmed on Friday. According to Kim Painter of USA Today, the medication is manufactured by Gilead Sciences and “can be paired with other drugs to make treatment of the liver-damaging disease faster, easier and more effective.” Dr. Edward Cox, director of the...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....

2013-12-04 12:23:25

The Strongest Dynamic Decreasing Sales in the HIV Market is Generic Erosion of Key Antiretroviral Drugs, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that major-market sales of antiretroviral (ARV) drugs for HIV will decrease marginally over the next decade, from an estimated $13.4 billion in 2012 to $13.1...

2013-11-27 08:24:00

NEW YORK, November 27, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Forest Laboratories Inc. (NYSE: FRX), and Envision Healthcare Holdings, Inc. (NYSE: EVHC). Today's readers may access these reports free of charge - including full price...

New Technology Combining Contraception, HIV And Herpes Simplex Virus-2 Prevention
2013-11-12 12:19:08

CONRAD Multipurpose prevention technologies featured at AAPS Annual Meeting and International Conference on Family Planning CONRAD Head of drug delivery, Meredith Clark, PhD, today presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas. This multipurpose prevention technology (MPT) can remain in the...